ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

TRX Tissue Regenix Group Plc

61.50
0.00 (0.00%)
Last Updated: 08:00:27
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix Group Plc LSE:TRX London Ordinary Share GB00BNTXR104 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 61.50 61.00 62.00 61.50 61.00 61.50 6,432 08:00:27
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 29.49M -302k -0.0043 -143.02 43.4M
Tissue Regenix Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker TRX. The last closing price for Tissue Regenix was 61.50p. Over the last year, Tissue Regenix shares have traded in a share price range of 49.00p to 71.50p.

Tissue Regenix currently has 70,574,468 shares in issue. The market capitalisation of Tissue Regenix is £43.40 million. Tissue Regenix has a price to earnings ratio (PE ratio) of -143.02.

Tissue Regenix Share Discussion Threads

Showing 8076 to 8100 of 14750 messages
Chat Pages: Latest  326  325  324  323  322  321  320  319  318  317  316  315  Older
DateSubjectAuthorDiscuss
09/1/2015
13:16
A severe lack of interest here, but there is a little bit of interest elsewhere!

Lack of info doesn't help, does it?😫

rayrac
17/12/2014
16:24
bobs, that was good timing. By the time I got things together it was 20p to buy.

Odell made much during the recent presentation, of the fact that our NHS clinical trial dermis patients in the UK were a truly random selection, with one man having had a non-healing wound for 40 years. The US Doctors involved with their trial, were amazed that the co had included such difficult cases.
It seems that some of the folk being treated with Dermapure now are those that have been failed by competitors products. Many are making good progress.

bamboo2
17/12/2014
14:50
FYI bb2, tradeplan executed @ 19.85 (£3595) on my ISA account this morning.

Ideally want to see the first complete heal case study from a one of those early U.S practioner's now.

bobsgonnamakemerich
17/12/2014
11:41
Late trade of 200k at 19.5 just reported, must be responsible for the drop earlier. Wonder I f I can top up under 20p?
bamboo2
17/12/2014
09:13
Listened to the Webcast. Very little new to add to the CMD.

Significant interest in the Heart Valve product has been recieved from da Costas presentations.

Potential new products mentioned are a hip arthroscopy repair involving Osteo/cartilage plugs. I think Ingham and Fisher have been working on this idea for some time with dCell Meniscus.

Interestingly, Woodford added about a week after this presentation.

bamboo2
10/12/2014
22:36
Link for webcast from Jefferies 2014 Global Healthcare Conference:



Currently, I can't get the webcast to play consistently, but the slides are viewable.

bamboo2
05/12/2014
11:33
I suspect Woodford will add if price drifts below his buy-in price.
igbertsponk
05/12/2014
11:31
Thanks, bamboo. Also thanks for the excellent research you post here. Agree chart looks drifty down in short term but hoping news will reverse that in good time.
luminoso
05/12/2014
10:13
luminoso, welcome. Chart is not looking too hot, but share price does look to offer a good entry point. Woodfords new interest here is positive, and I prefer to see him as a significant holder than Griffiths.

img src="http://uk.advfn.com/p.php?pid=chartscreenshot&u=Uzqer2HeZIpB3xiYKKtDMRCf4B+n0IL+">

bamboo2
04/12/2014
12:45
The trades of 20.75 and above are buys today, possibly even the 20.5 trades, as buy price has been around or below the bid for days on most quotes I have had. Nice 220k buy also. Not mine, sadly, but I do have a foot in the door now.
luminoso
01/12/2014
17:55
As at 1 December 2014, shareholders holding more than 3% of the share capital of Tissue Regenix Group Plc are:

• Invesco Limited - 27.88% [Invesco formerly held 29%, implying that WIM originally inherited 1.12% on behalf of St James Place]
• Techtran Group Limited - 13.74% [aka ipo group]
• WIM [WOODFORD] on behalf of St James Place 12.46% [81,478,587][Purchased RGriffiths/ORA Cap holding]
• NFU Mutual - 4.66%
• University of Leeds - 5.19%
• Ballie Gifford & Co Ltd - 5.64% [36,870,574] Adding.
• IP Venture Fund - 3.79% [aka ipo group]
• John Samuel [Chair] – 3.71%
• Alan Miller [NED]– 3.29%

Larger known shareholders as at 1 Dec 2014 - Approx - 80%

Shares in issue 654,123,031 ordinary shares of 0.5p each

==================
from ipo group half yr figs 28/08/14 [directors personal holdings in TRX]
Alan Aubrey 2,389,259 0.4%
Mike Townend 1,950,863 0.3%
Greg Smith 175,359 <0.1%
Charles Winward 482,236 <0.1%
Bruce Smith 329,172 <0.1%
Charles Winward resigned from the Board on 23 April 2014 [Could be a seller?]

bamboo2
01/12/2014
10:52
Confirmed it was Richard Griffiths who sold.
Good news as it means Invesco wouldn't sell any of theirs to Woodford like they have with a lot of their investments.

igbertsponk
28/11/2014
17:23
Woodford holds 81,478,587 or 12.46% presumably on behalf of St James Place.

I'll amend the holdings list once we have confirmation of the seller.

bamboo2
28/11/2014
15:25
Mind you, if the price of oil remains around its present level... Then industry will benefit!
rayrac
28/11/2014
14:04
This market is in a bad mood. Hope it doesn't extend itself, a growling bear?
rayrac
28/11/2014
11:35
Validation!
rayrac
28/11/2014
10:31
Brill news. Woodford has been taking chunks of Invesco holdings on other companies. Clearly they didn't want to sell here but he wants in anyway.
igbertsponk
28/11/2014
09:49
Woodford announcing going through 12%. Did they take Griffiths holding ? Another rns surely due.
luminoso
28/11/2014
08:11
Re, the Dcell Meniscus product. There are two new papers available,

1, Describes the UK patent


2, Gives a short history of the development of various previous attempts to create replacement menisci, and explains why our product is important. Titled, 'Current strategies in meniscal regeneration'

bamboo2
26/11/2014
15:51
If it is a Griffiths sale then I would welcome it.

I've watched his holding style here and in other tech stocks and whilst I have no hard evidence, I believe he sells into share price rises, which serves to negate the benefit of good news.

Hopefully we will see firmer, more patient hands, holding his shares.

Can't complain at the lack of volume now. :-)

There is a small amount of stock on loan, here is the link to a chart of short interest for trx. I can't post as I am black, but if any of you blues fancy posting this image?
[ps, I'm not sure the link is correct, but it is viewable in post no 9 earlier in this thread]

target='window'>hxxps://api.dxopen.com/DxlApi/Chart.aspx

bamboo2
26/11/2014
12:50
Well Invesco would perhaps sell to Woodford's new fund. Techtran have just raised another £100m so have no need of the cash.
So I agree, looks like Richard Griffith. Perhaps selling for tax reasons as he may fear a Labour government would tax his gain. So running offshore with the moolah now.

igbertsponk
26/11/2014
12:49
Just seen that Sharecast.com puts Richard Griffith's holding at 71,602,551. Don't need to be Sherlock Holmes on this one.

Here's the link:

andrewbaker
26/11/2014
12:43
71602551/654120000 = 10.946393781%

What's the odds that Richard Griffith just sold out, lol.

andrewbaker
26/11/2014
12:33
Into a bidders hands perhaps? But the price isn't stellar!
rayrac
26/11/2014
11:32
Can only be one of these three selling :
Invesco Limited 27.88%
Techtran Group Limited 13.74%
Richard Griffiths 10.95%

igbertsponk
Chat Pages: Latest  326  325  324  323  322  321  320  319  318  317  316  315  Older